GSK3B and Parkinson disease: Moreover, 1-methyl-4-phenylpyridinium (MPP+) induced PD features such as the impairment of motor function, α-synuclein accumulation, and neurotoxicity, which could be abrogated by GSK-3β inhibitors [12].